{"id":7399,"date":"2005-04-18T09:12:44","date_gmt":"2005-04-18T08:12:44","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=7399"},"modified":"2014-05-21T18:40:56","modified_gmt":"2014-05-21T18:40:56","slug":"pegasys-approved-in-the-european-for-the-treatment-of-chronic-hepatitis-b","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/7399","title":{"rendered":"Pegasys approved in Europea for the treatment of chronic hepatitis B"},"content":{"rendered":"<p><strong>On 25 February, the EU Commission approved Pegasys (peginterferon alfa-2a (40KD)) for the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B.<\/strong><\/p>\n<p>The phase III study results on which approval was based in HBeAg-negative chronic hepatitis B were published in September 2004 in the New England Journal of Medicine. The results of the phase III study in patients with HBeAg-positive CHB were presented at the 2004 Annual Meeting of the American Association for the Study of Liver Diseases.<\/p>\n<p>Studies in HIV\/HBV coinfected patients are still needed.<\/p>\n<p>Source: Roche press release.<br \/>\n<a href=\"http:\/\/www.roche.com\">http:\/\/www.roche.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 25 February, the EU Commission approved Pegasys (peginterferon alfa-2a (40KD)) for the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B. The phase III study results on which approval was based in HBeAg-negative chronic hepatitis B were published in September &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-7399","post","type-post","status-publish","format-standard","hentry","category-hepatitis-coinfection"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/7399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=7399"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/7399\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=7399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=7399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=7399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}